PsyGen Labs Inc. is a GMP-compliant manufacturer of pharmaceutical-grade psychedelic drug products for clinical research and therapeutic applications.
The company became the first manufacturer of restricted psychedelic drug products licensed by Health Canada. The facility is licensed to manufacture psilocybin, MDMA, LSD, DMT, mescaline and 2C-B. All of these drug products comply with domestic and international regulations and meet strict drug approval protocols.
The company is building a cGMP compliant manufacturing facility dedicated to the synthesis and formulation of psychedelic drug products for clinical research and approved therapeutic applications. Its business model is designed to advance psychedelics along the drug approval pathway and facilitate access for clinicians and patients.
Management Team
Danny Motyka
CEO
Peter van der Heyden
CSO
Mark Haden
Advisor